Veracyte Stock Price, News & Analysis

Veracyte, Inc. (Nasdaq: VCYT) has launched an underwritten public offering to sell $400 million in common stock, with an option for underwriters to purchase an additional $60 million. Proceeds will primarily fund the acquisition of Decipher Biosciences, Inc., alongside working capital and general corporate purposes. The offering is backed by Goldman Sachs & Co. LLC and SVB Leerink LLC as lead managers. The shares will be issued under an effective shelf registration statement filed with the SEC.

Veracyte (Nasdaq: VCYT) has announced its acquisition of Decipher Biosciences, a leader in precision oncology focused on urologic cancers, for $600 million. This deal, comprising $250 million in cash and up to $350 million in stock, aims to enhance Veracyte's genomic testing capabilities across seven prevalent cancers in the U.S. Decipher's revenue grew over 130% in 2020 to approximately $39-$40 million. The combined entity expects annualized revenue of about $186 million and an expanded addressable market from $10 billion to $12 billion. Completion is anticipated by May 2021, pending regulatory approval.

Veracyte, Inc. (Nasdaq: VCYT) announced preliminary results for Q4 and FY 2020, projecting total revenue between $34.0 million and $35.0 million for the fourth quarter, and between $117.0 million and $118.0 million for the full year, reflecting a 16% increase in Q4 revenue year-over-year. Testing volume also rose by 14% compared to 2019. The company expects cash equivalents of $345.0 million to $350.0 million as of year-end. CEO Bonnie Anderson highlighted the team's performance and robust pipeline as key to future growth.

Veracyte, Inc (Nasdaq: VCYT) announced that its CEO Bonnie Anderson will present at the 23rd Annual Needham Virtual Growth Conference on January 13, 2021, at 4:15 p.m. ET. A live audio webcast of the presentation will be accessible via the company’s website, with a replay available for 90 days thereafter. Veracyte is a global genomic diagnostics company focused on improving patient care through advanced genomic testing for diseases such as cancer.

Bayer and Veracyte are collaborating to enhance the Precision Oncology Patient Identification Program for thyroid cancer. This initiative will utilize Veracyte's Afirma Xpression Atlas to detect genomic drivers, including NTRK gene fusions, in patients with advanced or radioactive iodine refractory (RAIR) thyroid cancer. The program will provide Afirma XA testing at no cost for eligible patients, supporting informed treatment decisions. Launched in Q1 next year, it aims to help patients with actionable alterations access targeted therapies, impacting approximately 53,000 annual thyroid cancer diagnoses in the U.S.

Veracyte, Inc. (Nasdaq: VCYT) has revealed preliminary performance data for its noninvasive nasal swab test aimed at early lung cancer detection and the Percepta Genomic Atlas for treatment decisions. Scheduled for launch in late 2021, these tests leverage genomic profiling to cater to patient needs. Initial data indicated that 44-60% of malignant nodules were correctly classified as high-risk, with high specificity (90-91%). Additionally, the Percepta Genomic Atlas demonstrated over 95% accuracy in detecting gene variants in lung cancer. Veracyte continues its commitment to enhancing lung cancer diagnostics.

Veracyte, a global genomic diagnostics company, will host a Virtual Lung Cancer R&D Day on December 16, 2020, from 10:00 a.m. to 12:00 p.m. EST. The event will showcase senior management discussing the company’s vision for lung cancer patient care and updates on its product pipeline including the Nasal Swab Test and Percepta Atlas, set to launch in the second half of 2021. Investors can register for the event here.

Veracyte, a global genomic diagnostics company, announced that CEO Bonnie Anderson will participate in a fireside chat and one-on-one meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The pre-recorded chat will be available on the conference website, with a replay accessible on Veracyte's site for 90 days post-event. Veracyte provides genomic tests for various cancers, improving patient care by enabling quicker diagnoses and treatment decisions. For more information, visit www.veracyte.com.